A New York judge has confirmed an outside monitor in the Endo International bankruptcy. Prof. Jonathan Lipson says it’s a move straight out of the Purdue playbook. Read More

The FTX bankruptcy will shine a light on the world of cryptocurrency and require lawyers to find analogies that will help judges understand its complexities, says Prof. Jonathan Lipson. Read More

Prof. Jonathan Lipson addresses concerns that FTX’s bankruptcy could spill over into the general economy much like Lehman Brothers’ did just before the Great Recession. Read More

Prof. Jonathan Lipson says pre-bankruptcy bonuses paid to Endo executives raise important questions about whether management was pillaging the company or paying employees fairly. Read More

Malvern-based opioid manufacturer Endo paid out millions in two rounds of bonuses to corporate leaders in the months before filing for bankruptcy. Prof. Jonathan Lipson says people should ask why the company is rewarding those who oversaw its demise. Read More

Prof. Jonathan Lipson says that opioid manufacturer Endo’s bankruptcy litigation doesn’t seem to have any “highly visible bad guys,” a marked difference from cases like Purdue Pharma. Read More

Professor Jonathan Lipson joins the ABA Business Law Section’s Book Chat to discuss the Model Business Corporation Act – Annotated, for which he was a co-editor.  Read more.

Prof. Jonathan Lipson discusses vertical forum shopping in Chapter 11 litigation and its implications for the dignitary interests of personal injury creditors on Harvard Law School’s Bankruptcy Roundtable. Read more.

Prof. Jonathan Lipson says that a federal judge’s decision to re-open the Purdue Pharma bankruptcy vindicates those who expressed concern about the Sacklers’ escape from liability under the deal, but is otherwise “no cause for celebration.” Read more at MSN News.

Prof. Jonathan Lipson is joined by other bankruptcy experts in exploring what’s next for the Purdue Pharma bankruptcy plan. Read more at STAT.